Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
View Patent ↗Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively modulating the fetal programming of the immune system for the purpose of preventing or treating immune-modulated diseases. The disclosure also provides interventions to protect offspring and immunized subjects against insulin resistance.
1. A method of immunization, comprising administering an antigen containing epitopes formed by oxidation or glycation of a phospholipid to a pregnant subject or soon to be pregnant subject, wherein the immune response in the pregnant subject or soon to be pregnant subject induces non-passive immune programming in the resulting offspring to the antigen, so that the resulting offspring produces IgG and IgM, or IgM antibodies to the antigen, wherein the antigen is selected from LDL, HDL, VLDL, IDL and LP(a), peptides of apolipoprotein B-100 or other apolipoproteins, or phospholipid components of lipoproteins.
2. A method of fetal immune programming comprising administering an antigen containing epitopes formed by oxidation or glycation of a phospholipid to a pregnant female subject or soon to be pregnant female subject, wherein the immune response in the female subject induces non-passive fetal immune programming during pregnancy so that the resulting fetus produces IgG and IgM, or IgM antibodies to the antigen, wherein the antigen is selected from LDL, HDL, VLDL, IDL and LP(a), peptides of apolipoprotein B-100 or other apolipoproteins, or phospholipid components of lipoproteins.
3. The method of claim 1 or 2 , wherein said method of administration comprises oral, intravenous, parenteral, transdermal, subcutaneous, intravaginal, intraperitoneal, intranasal, mucosal, sublingual, topical or rectal administration, or any combination thereof.
4. The method of claim 1 or 2 , wherein the antigen is selected from the group consisting of an antigen that induces autoimmune disease, and an autologous antigen.
5. The method of claim 1 or 2 , wherein the antigen comprises a neoepitope formed by oxidation, glycation, or a combination thereof.
6. The method of claim 4 , wherein the disease or disorder comprises atherosclerosis, obesity, insulin resistance, the metabolic syndrome, non-insulin dependent diabetes mellitus (NIDDM), and insulin dependent diabetes mellitus (IDDM).
7. The method of claim 4 , wherein the autoimmune disorder is IDDM.
8. A method for treating or reducing the risk of developing an autoimmune disorder comprising administering to a pregnant maternal subject or soon to be pregnant maternal subject, an immunomodulatory effective amount of at least one epitope from a self-antigen comprising epitopes formed by oxidation or glycation of a phospholipid in a pharmaceutically acceptable carrier, wherein the epitope induces a non-passive immune response in the maternal subject and wherein the maternal subject's immune response provides immune programming in a fetus, so that the fetus produces IgG and IgM, or IgM antibodies to at least one epitope of the self-antigen, wherein the antigen is selected from LDL, HDL, VLDL, IDL and LP(a), Peptides of apolipoprotein B-100 or other apolipoproteins, or phospholipid components of lipoproteins.
9. The method of claim 8 , wherein the subject is a human.
10. The method of claim 8 , wherein the autoimmune disorder is diabetes.
11. The method of claim 8 , wherein the epitope comprises an antigen selected from the group consisting of an antigen that induces autoimmune disease, and an autologous antigen.
12. The method of claim 8 , wherein the antigen comprises an oxidative neoepitope.
13. The method of claim 11 , wherein the disease or disorder comprises atherosclerosis, obesity, insulin resistance, the metabolic syndrome, non insulin dependent diabetes mellitus (NIDDM), and insulin dependent diabetes mellitus (IDDM).
14. A method of inducing protective immunity in a subject comprising administering an antigen containing epitopes formed by oxidation or glycation of a phospholipid to a female subject just prior to or during pregnancy so that upon the birth the subject comprises a programmed immunity to the antigen, by producing IgG and IgM, or IgM antibodies to the antigen, wherein the antigen is selected from LDL, HDL, VLDL, IDL and LP(a), peptides of apolipoprotein B-100 or other apolipoproteins, or phospholipid components of lipoproteins.
15. The method of claim 14 , further comprising boosting the programmed immunity of the subject after birth, comprising administering the antigen to the neonate subject.
16. The method of claim 1 , comprising administering an antigen containing epitopes formed by oxidation or glycation of a phospholipid to a pregnant subject, wherein the immune response in the pregnant subject induces non-passive immune programming in the resulting offspring to the antigen, so that the resulting offspring produces IgG and IgM, or IgM antibodies to the antigen.
17. The method of claim 8 , comprising administering to a maternal subject during pregnancy, an immunomodulatory effective amount of at least one epitope from a self-antigen comprising epitopes formed by oxidation or glycation of a phospholipid in a pharmaceutically acceptable carrier, wherein the epitope induces a non-passive immune response in the maternal subject and wherein the maternal subject's immune response provides immune programming in a fetus, so that the fetus produces IgG and IgM, or IgM antibodies to at least one epitope of the self-antigen.
18. The method of claim 14 , comprising administering an antigen containing epitopes formed by oxidation and glycation of a phospholipid to a female subject during pregnancy so that upon birth of the subject, the subject has programmed immunity to the antigen, by producing IgG and IgM, or IgM antibodies to the antigen.